Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 most promising mid-cap healthcare stocks according to hedge funds. On May 15, the price target on Tango Therapeutics Inc. (NASDAQ:TNGX) was ...
Venture capital fund Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025. Third Rock Ventures IV, L.P. is a 10% owner in Tango Therapeutics. How significant was ...
Investors considering a purchase of Tango Therapeutics Inc (Symbol: TNGX) shares, but cautious about paying the going market price of $11.97/share, might benefit from considering selling puts among ...
Opinion
23dOpinion
Tango Therapeutics (TNGX) Is Down 10.7% After Pipeline Pivot And Board Changes - Has The Bull Case Changed?
Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of ...
Tango Therapeutics, Inc. (TNGX) shares rallied 10.3% in the last trading session to close at $8.39. This move can be attributable to notable volume with a higher number of shares being traded than in ...
Tango Therapeutics, Inc. recently reported first-quarter 2026 results showing a net loss of US$45.51 million, no collaboration revenue after its Gilead research term ended, and the resignations of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results